Insider Radar — Week of June 22, 2026

Insider selling always dwarfs buying, and this week it ran at $13.40 sold per dollar bought, right at the recent norm. The catch: the biggest 'buys' were a biotech financing round, an IPO-priced allocation taken by five insiders at one fixed price, and a controlling holder accumulating preferred, not fresh conviction.

884
$276.4M
top three names are financings
$3.69B
38% scheduled plans
13.4×
vs 14.3× recent median

Insiders sold about $13.40 for every $1 they bought, right at the recent norm of ~14×. And the top of the buy list wasn't conviction: a $90M biotech financing round at Kardigan, a $75.8M IPO-priced allocation at DPC Holdings taken by five insiders at a flat $33.00, and ~$20M of preferred-share accumulation by Liberty Latin America's controlling holder.

KARD$90.0M
DPC$75.8M
LILA$32.6M
CGON$24.8M
COE$17.7M
PAM$4.7M
PSEC$4.7M
BNR$3.0M

The buying wasn't really conviction

$276M of insider buying looks meaningful until you unpack the top of it. The single largest block, $90M into Kardigan (KARD), was venture backers (ARCH Venture Partners, HRTG and board member Paul Berns) crossing the 10% ownership line in a financing round at a flat $16.00. It shows up on Form 4, but it isn't open-market conviction. The second name is the same pattern at a different stage: five DPC Holdings (DPC) insiders, including the CEO and CFO, reported $75.8M of stock at a uniform $33.00 on June 26. One price across five filers on one day is an offering allocation being reported, not five people deciding the stock is cheap.

The #3 name, $32.6M in Liberty Latin America (LILA), was John Malone. But about $20M of that was accumulation of Series A preferred shares (a fixed-income-like instrument) by the controlling shareholder during a special-dividend consolidation, not a directional equity bet. Strip out the financings and the preferred, and the week's genuinely directional open-market conviction was modest: a $24.8M director buy at CG Oncology (CGON) and $17.7M from 51Talk's founder-CEO (COE), plus small, habitual CEO buys at Prospect Capital and Nexstar.

KARDARCH Venture, HRTG, Paul Berns10% owners (financing)$90.0M
DPCFive insiders incl. CEO and CFOOfficers and directors (offering)$75.8M
LILAJohn MaloneControlling holder$32.6M
CGONBrian LiuDirector$24.8M
COEJack HuangCEO / founder$17.7M
PAMMarcos MindlinDirector$4.7M
PSECJohn BarryChairman & CEO$4.7M
BNRYusheng HanDirector$3.0M

The selling was mostly funds and scheduled plans

Insiders sold $3.69B on the week (with dispositions above $1B per event excluded as reorganization-scale). At 13.4× the buying that sounds extreme, but insider selling is structurally lopsided (options, diversification, liquidity), and recent weeks have run a median of about 14×, so this week sat right at the norm.

About 38% of it, $1.40B, was pre-scheduled 10b5-1 plan selling that carries no current-quarter signal, including $250M at Broadcom (AVGO) and $64M at Oracle (ORCL). The largest discretionary sales were funds trimming positions, not executives leaving their own companies: Spyre Therapeutics (Fairmount, $400M), Dollar Tree (activist Mantle Ridge, $248M) and Kymera (BVF Partners, $168M). One block deserves a footnote: a $177M sale of WaterBridge Infrastructure (WBI) stock on June 22 appears three times in the filings, reported by three related holding entities over the same shares, with Devon Energy separately selling $52.7M. Post-IPO distributions by a control group look like a wave of selling in the raw feed; economically it is one exit.

SYREFairmount Funds Management10% holder$399.7MOpen marketJun 23
AVGOHenry SamueliDirector$250.0M10b5-1Jun 24
DLTRMantle Ridge LPActivist fund$248.3MOpen marketJun 24
WBIWaterBridge control group10% holders (co-filed)$177.1MOpen marketJun 22
KYMRBVF Partners10% holder$168.1MOpen marketJun 26
PRMWindAcre Partnership10% holder$117.6MOpen marketJun 26
ORCLJeffrey HenleyVice Chairman$63.7M10b5-1Jun 24
WBIDevon Energy10% holder$52.7MOpen marketJun 22

Covers every SEC Form 4 filed on EDGAR during June 22–28, 2026, grouped into economic events by transaction code and ownership form and scored on the summed value of the group. Events above $1 billion are excluded: at insider scale these are almost always M&A, tender, or reorganization dispositions (or filer errors), not tradeable insider activity. 'Buying' and 'selling' sum non-derivative purchase (P) and sale (S/D) transactions. The sell/buy ratio is compared to the median of recent steady-state weeks with over $10M of buying (14.3×, from 6 weeks; filing coverage matured in mid-2026, so the baseline is short). LILA's common-vs-preferred split is inferred from per-share price pending a structured security-class field. Restated on August 6, 2026: a coverage gap in our Form 4 collector, found and fixed that day, had dropped a share of filings for this window. The figures above reflect the complete set backfilled from SEC's daily indexes; the originally published issue reported 784 filings, $192.3M of buying and $3.57B of selling. This is a filtered readout of public filings, not investment advice.

Sources: SEC EDGAR (Form 4 filings)

Get this data live

These figures come straight from the alphai feed. Pull scored SEC Form 4 filings and financial news programmatically via the API and MCP server, or set a free alert on any ticker.